Follow Us

Menu
Log in
Log in

John Tavis

 

Member profile details

Membership level
Drug Discovery Center
First name
John
Last name
Tavis
Degree(s)
  • PhD
Job Title
Director, SLU-IDBI
Organization
Saint Louis University
Department
Institute for Drug & Biotherapeutic Innovation
City
St. Louis
State / Province
Missouri
Country
United States
Zip / Postal Code
63103
DDC Logo avatar
DDC Website URL
DDC Affliliation(s)
Saint Louis University
DDC Center / Program Name
Saint Louis University Institute for Drug and Biotherapeutic Innovation (IDBI)
DDC Center / Program Description
The Saint Louis University Institute for Drug and Biotherapeutic Innovation leverages the expertise of 100+ members in medicine, biology, engineering, computational and applied chemistry to discover, develop and translate new medical therapies. As a decentralized, collaborative institute, we provide:
1. Education to our members and students on drug discovery and development,
2. Drug discovery consultations, seed grants, and other tools to members to advance translational projects
3. Facilitate intra and inter-institutional translational collaborations.

The IDBI operates physical and virtual service cores to provide access to key drug development steps such as assay development, compound screening/counter screening, ADME/PK, and medicinal chemistry drug optimization. The broader SLU research community also offers access to world class vivarium facilities, and world leaders in vaccine and therapeutic clinical trials through the Center for Vaccine Development.

As an academic-based drug discovery institute, IDBI educates students at all levels of their career. IDBI members teach classes, mentor students, and welcome both graduate and undergraduate students into their labs, expanding classroom education into real-world research experience.
DDC Director Name
John Tavis
Year Established
2017
Employees in Program
70
Therapeutic Approaches
  • Antibodies
  • Biologics
  • Drug Delivery
  • Drug Devices
  • Gene Therapy
  • Small Molecules
  • Vaccines
Therapeutic Areas of Focus
  • Immunology
  • Infectious Diseases
  • Metabolic Disorders
  • Neurological Disorders
  • Oncology
  • Pain
  • Regenerative Medicine
  • Virology
Funding Source Types
  • Disease Foundations
  • Federal/State
  • Foundation
  • Industry Partnerships
  • Internal
  • NIH
  • Philanthropy
  • University
Current Project Description
The Tavis Lab’s primary focus is antiviral drug discovery targeting the Hepatitis B Virus ribonuclease H (RNaseH). The lab has developed a suite of biochemical and cell-based assays to evaluate how inhibitors of the RNaseH affect the enzyme and viral replication. Its key resource is a small but chemically diverse set of nuclease inhibitors and their analogs. The lab routinely conducts cytotoxicity assays using MTS (mitochondrial function), neutral red retention (lysosome function), crystal violet retention (DNA accumulation, usually interpreted as cell growth), and LDH release (plasma membrane integrity) to gain a more comprehensive view of how its compound affects the cell. The lab collaborates with medicinal chemists in the United States, France, Greece and China and is actively pushing forward two anti-HBV RNaseH hit-to-lead optimization projects. They work closely with other members of the SLU-IDBI, including Feng Cao, Ph.D.; Maureen Donlin, Ph.D.; Lynda Morrison, Ph.D.; and Getahun Abate, Ph.D. Through these collaborations, the lab has demonstrated that the inhibitors in its library can have high selectivity for one virus or cellular organism over the others, opening a pathway to antimicrobial development targeting nucleases.

Contact us

Powered by Wild Apricot Membership Software